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SUMMARY
Hairy cell leukaemia (HCL) is a rare B cell malignancy
that is associated with the BRAF V600E mutation and
has good treatment response to purine analogues. Its
presentation synchronously with other malignancies
has been rarely reported. Here, we present a patient
with HCL with hepatic involvement who was also found
to have pancreatic adenocarcinoma concomitantly
at the time of diagnosis. Treating these rare cases
simultaneously is a challenge clinically. Throughout this
case study, we provide our approach on how oncological
care teams provided care for this complicated and rare
disease state.

tests and bilirubin levels concerning for an obstructive process. Abdominal imaging showed multiple
hepatic masses consistent with metastasis. Endoscopic ultrasound revealed a hilar mass, biopsy-
confirmed pancreatic adenocarcinoma. However,
a subsequent liver biopsy was performed which
was positive for HCL infiltrates. This is a rare case
of HCL with liver involvement in the setting of
pancreatic adenocarcinoma.

CASE PRESENTATION

We present a woman in her 70s with a medical
history of insulin-dependent type 2 diabetes, hypertension, stage IIIA chronic kidney disease, diverticulosis and acid reflux disease who came to the
BACKGROUND
emergency department in January 2022 with weakHairy cell leukaemia (HCL) is a rare, chronic B-cell ness, fatigue and a 6-month 20-pound weight loss.
malignancy that affects primarily the bone marrow, She was also found to be in diabetic ketoacidosis on
spleen and the peripheral blood. Patients usually admission and was COVID-19 positive. On admispresent with pancytopenia along with systemic sion, the patient was found to have a normocytic
symptoms such as fatigue and weight loss. Median hypochromic anaemia of 8.4, a bilirubin of 1.9,
age of diagnosis is 55 years of age and male patients an elevated alkaline phosphatase of 465, with an
are disproportionately more affected ascompared AST and ALT level of 42 and 30, respectively. Of
with female patients with a ratio of 4:1.1 Most note, her liver function tests and bilirubin level
cases are caused by V600E BRAF gene mutation of were normal 6 months prior to presentation. Blood
late activated memory B cells. Treatment is usually cultures were found positive for gram negative
reserved for symptomatic patients who experience bacteria consistent for Escherichia coli. Physical
fatigue or symptomatic splenomegaly, and first- examnation was consistent with mild splenomegaly.
line treatment consists of the purine analogues of She was started on antibiotics with ceftriaxone and
cladribine or pentostatin.1
metronidazole with a gastroenterology consult.
Pancreatic cancer is the second most common
Due to the patient’s weight loss, a CT scan of
gastrointestinal malignancy in the USA.2 Patients the abdomen and pelvis was obtained a couple of
usually present with worsening abdominal pain, weeks prior to hospitalisation by her primary care
weight loss, jaundice and lab results indicative of an physician showing non-
specific diffuse moderate
obstructive process with an elevated bilirubin and small bowel wall thickening involving the majority
liver function tests. These patients usually present of jejunal and ileal loops as well as hyperdense
late in the disease process and their malignancy is 10 mm cephalic hyperdense structure arising within
far too advanced to cure. The only curative treat- the midpole of the left kidney, which may relate to
ment for pancreatic cancer is surgery, however, a proteinaceous or haemorrhagic cyst. During her
that only happens in roughly 15% of patients given admission, repeat abdominal imaging with an MRI
the presentation of the disease is at its final stages of the abdomen and pelvis showed pancreatic duct
where the tumour is no longer resectable.2 Adju- dilation up to 5 mm and common duct dilation
vant and neoadjuvant chemotherapy such as FOLF- along with a numerous T2 bright hypovascularised
IRINOX (folinic acid, fluorouracil, irinotecan, hepatic masses present with some of the masses
oxaliplatin) or gemcitabine plus nab-paclitaxel or being hyperintense in nature. These masses are new
gemcitabine alone are typically used based on the when compared with the previous CT scan.
patient’s performance status.2 Here, we present a
Given the pancreatic duct dilation, gastroenpatient in her 70s who presented to the emergency terology proceeded with oesophagogastroduodepartment for worsening fatigue and weight loss. denoscopy, which showed a malignant duodenal
She was found to have an elevated liver function ampullary mass with intermittent spontaneous
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Figure 1 Ampullary biopsy showing adenocarcinoma.
oozing. This was followed by an endoscopic ultrasound was then
done, and it showed a mass in the ampulla extending beyond
the duodenal wall on to the pancreatic head with dilation of
the main bile duct up to 15 mm and pancreatic duct dilation
up to 7 mm. A biopsy of the mass showed malignant cells that
were suspicious for adenocarcinoma from a pancreatic primary
(figure 1).
Given the patient’s pancytopenia with a haemoglobin of 8.4,
white cell count of 3.9 and a platelet count of 140K, a peripheral
smear was obtained. Peripheral smear showed pancytopenia with
monocytopenia and lymphopenia as well as occasional atypical
lymphocytes with reniform nuclei, spongy grey-blue cytoplasm
and hairy-like protrusions resembling hairy cells. Concurrent
negative/CD10-
flow cytometry shows a population of CD5-
negative monotypic B-cells with immunophenotype suspicious
for HCL. This necessitated a haematology consult. The haematology service arranged for a bone marrow aspirate/biopsy
V600E
(figure 2) as well as molecular testing of the BRAF-
mutation to confirm the diagnosis. The patient was found to
be BRAF- V600E positive. At that time, the patient was feeling
better symptomatically and was cleared for discharge with urgent
follow-up in the outpatient setting.

Figure 3 Liver biopsy H&E staining showing benign liver parenchyma
with sinusoidal lymphocytic infiltrate and cholestasis. In addition, there
is focal fibrosis.

The bright CD45+cells with small-
to-
large lymphoid light
scatter are analysed by flow cytometry. These are a mixture of
mature T-lymphocytes and monotypic B-lymphocytes. The latter
show the following composite antigen profile:
Positive: CD11c (bright), CD19 (bright), CD20 (bright),
CD22, CD25, CD103 (subset), CD200 and immunoglobulin
lambda light chain (bright).
Negative: CD3, CD5, CD10, CD23, CD38, CD123 and
immunoglobulin kappa light chain. The above antigen profile
is positive for a CD5 negative/CD10 negative B-cell lymphoproliferative disorder (LPD), with immunophenotype suggestive
of HCL.

Immunostains

The atypical lymphoid cells are positive for CD20 and CyclinD1,
comprising ~70% of marrow cellularity. CD3 highlights scattered and clusters of T-cells in the background.
In the outpatient setting, a liver biopsy (figure 3) was obtained
to facilitate pancreatic cancer staging given the multiple hepatic
masses. The biopsy results were consistent with HCL (figure 4).
IGH gene rearrangement analysis was positive for clonality and
demonstrated a similar clone to that detected in the recent bone
marrow biopsy; therefore, consistent with involvement by HCL.
Her pancreatic cancer was hence staged according to the eight
th edition of AJCC at stage IB. She was presented at the pancreatic multidisciplinary tumour board meeting as well as malignant
haematology tumour board meeting for discussion.

TREATMENT

Figure 2 Bone marrow biopsy showing evidence of hairy cell
leukaemia. details of immunophenotype as described.
2

Given that the patient had two primary malignancies that needed
to be treated, the management was a little tricky. The consensus
as per medical oncology and haematology was to initially treat
the patient’s HCL with rituximab with goal to put the patient
into remission and then proceed with further management of
her pancreatic adenocarcinoma, whether surgical, radiation or
systemic therapy. We chose to treat the patient this way because
more than 70% of her bone marrow was involved with HCL
and she had significant pancytopenia that would have put her at
increased risk of myelotoxicity from pancreatic cancer chemotherapy regimens (whether treated as neoadjuvant or definitive).
Moreover, prolonged immunosuppression was anticipated if we
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Figure 4 Liver biopsy with CD20 staining showing evidence of
hairy cell leukaemia involvement in the liver. IGH gene rearrangement
analysis was positive for clonality and demonstrated a similar clone to
that detected in the recent bone marrow biopsy; therefore, consistent
with involvement by hairy cell leukaemia

chose to treat her HCL with cladribine, which could have further
complicated pancreatic cancer management. The prolonged
state of immunosuppression with cladribine as opposed to rituximab would have made her more of a poor surgical candidate in
terms of her pancreatic cancer. Unfortunately, the patient only
received three out of four infusions of rituximab before passing
away from a pulmonary embolus.

DISCUSSION

HCL is a rare and indolent LPD that is known for its late relapses.
Some patients could be observed without the need for treatment.
Treatment is needed when patients begin to experience symptoms usually from their pancytopenia. First-
line treatment is
usually with the purine analogues of cladribine or pentostatin.
What happens when there are two primary malignancies
that present at the same time? Which malignancy does the care
team treat for first? Here, we present a patient who presented
with two primary malignancies at the same time. The patient
presented for progressive weight loss and pancytopenia as well
as biliary duct dilation. Her workup showed a hepatic and an
ampullary mass that was found to be pancreatic adenocarcinoma. Given this picture, we initially believed the patient might
have had metastatic pancreatic cancer but while working up the
pancytopenia, the patient was also found to have HCL. Biopsy
of the live mass was taken, and it was consistent with HCL and
not pancreatic adenocarcinoma.
A case report reported by Acebo et al examined a patient that
presented with papillary cystic tumour of the pancreas with
coexisting HCL.3 The patient in this case report was diagnosed
with HCL and then 7 months later was found to have papillary
cystic tumour of the pancreas. After going through a thorough
literature review, they found no association between the two
cancers and treatment consisted of tumour resection, followed
by treatment for HCL with purine analogues. The patient was
treated adequately and made a good recovery.
This was not the first-time HCL presented as a liver mass.
Another case report done by Al-Za’abi et al described a case
of a 70-
year-
old patient who presented with anaemia and a
peripheral smear showed neoplastic cells with eccentric bland
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nucelli an irregular cytoplasmic membrane characterised by
fine filamentous projections that goes in line with a diagnosis
of HCL.4 A CT scan at the time showed a 3 cm liver mass. A
need core biopsy was done and showed neoplastic cells characterised by the same cells as described as above. The cells were
CD20+but CD5 and CD 10 negative. This was an interesting
case of HCL presenting as a liver mass. Sahar et al also wrote a
case report about a patient who presented with a liver mass and
was found to have metastatic HCL.5 The patient in this case was
treated with cladribine and had a good response.
The most interesting aspect of our case, however, is deciding
how to treat our patient. At one end, the patient has HCL that
can be well controlled with a favourable outcome but on the
other hand, she is also diagnosed with early-stage pancreatic
adenocarcinoma. Given her symptomatic presentation and cytopenia, we decided to treat her HCL first, improve her cytopenia
and then restage her pancreatic cancer and decide if she would
be a candidate for surgery. Giving the patient standard of care
regimen for HCL might have delayed her pancreatic cancer
treatment. Hence, we decided to treat her with rituximab first,
then address the pancreatic cancer. Depending on her clinical
course afterwards, a purine analogue was to be offered for definitive treatment of HCL.
The dilemma of the entire patient case was regarding the therapeutic choice for treatment. The primary goal was to treat the
patient’s pancreatic carcinoma but due to her severe cytopenia
due to the patient’s underlying HCL, we chose to treat her HCL
in hopes her cytopenia will recover to the point where she can
undergo treatment for her pancreatic malignancy. As presented
in the article, there are a couple of different regimens one can
chose from to treat HCL, but we chose to treat her with rituximab as we figured this will make her the least immunocompromised compared with other treatments such as cladribine or
pentostatin.
An article written by Naik and Saven explained when providers
should initiate therapy for HCL. They stated, patients should
receive some form of therapy when such patient is symptomatic
or when patients have a haemoglobin under 10 g/dL, platelets
less than 100×109/L and/or neutrophils less than 1.0×109/L.6
In our patient’s case, she has a haemoglobin of 8.4 g/dL and we
attributed this to her underlying HCL. We also anticipated, that
if we chose to treat her for her underlying pancreatic adenocarcinoma first, her haemoglobin will drop even further requiring
her to get support red blood cell transfusions.
Another article by Troussard and Grever looked at different
treatment options for patients with HCL. Usually, like most
of the literature suggests, first line therapy would be a purine
analogue such as cladribine or pentostatin, but if patients have
relapse with this therapy and their cancer cells express CD20,
like the patient in this case report, then rituximab can be an
option.7
To our knowledge, this is the first time a patient presented with
HCL and synchronous pancreatic adenocarcinoma. A relatively
similar case was presented by Salemis et al where the team was
discovered neuroendocrine colon carcinoma and HCL.8 In that
case, they presented a 69-year-old man who had bright red rectal
bleeding and colonoscopy showed a bleeding ulcerative mass
that was biopsied and showed poorly differentiated carcinoma
with histology showing a poorly differentiated neuroendocrine
carcinoma. The patient was also pancytopenic on presentation
and bone marrow biopsy releveled extensive infiltration by a
malignant LPD of B cell origin and further analysis confirmed
HCL. The treatment for this patient was interesting. The team
chose to start chemotherapy for HCL with pentostatin due to
3
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the patient’s pancytopenia and then adjuvant chemotherapy for
the neuroendocrine colon carcinoma with FOLFOX and Rituximab regimen. This was started 4 months after treatment with
pentostatin. The team chose to do this so the patient can tolerate
the haematological side of effects of systemic chemotherapy. The
patient did tolerate this chemotherapy regimen well but unfortunately had hepatic metastases 10 months after treatment.
In conclusion, we present a rare case of HCL that presented
concomitantly with stage IB pancreatic carcinoma. To our
knowledge, this is the first reported case of these two malignancies presenting together. HCL and pancreatic cancer individually
are relatively uncommon, so it is extremely unlikely for these
two malignancies to present simultaneously. Most important
question is, which malignancy do clinicians treat first and how
to tailor therapy so that complications of treating one cancer
does not affect treating the other malignancy.
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Learning points
► When treating for two malignancies presenting

simultaneously, it is best to treat the malignancy that is more
symptomatic, but keeping in mind the side effects of such
treatment.
► Try to use therapy that minimises immunosuppression so
patients can undergo treatment for the other malignancy
while minimising complications.
► More cases like these need to be presented for healthcare
teams to understand how to manage two malignancies (solid
and haematological) at the same time.
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